dual glp-1/gip agonist GIPR/GLP-1R therapies for diabetes and weight loss– Chemistry, Physiology and Clinical application Main physiological actions of the

Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons

Common side effects of liraglutide are mainly gastrointestinal, and can include nausea, vomiting, constipation, or indigestion

Along with this, the market is estimated to grow at a CAGR of around 3.66% during the forecast period, i.e., 2026-32

No GLP-1 weight loss patches are currently approved by the MHRA (Medicines and Healthcare products Regulatory Agency)

For broader clinical context, the ADA Standards of Care provide evolving guidance on indications, monitoring, and safety considerations for GLP-1based therapies